July 19, 2021
Rose
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
from NYT > Health https://ift.tt/3imHC2y
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment